| Style | Citing Format |
|---|---|
| MLA | Balighi K, et al.. "Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?." Journal of Dermatological Treatment, vol. 29, no. 8, 2018, pp. 745-746. |
| APA | Balighi K, Ansari MS, Mirzaiepour M, Daneshpazhooh M, Mahmoudi H (2018). Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?. Journal of Dermatological Treatment, 29(8), 745-746. |
| Chicago | Balighi K, Ansari MS, Mirzaiepour M, Daneshpazhooh M, Mahmoudi H. "Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?." Journal of Dermatological Treatment 29, no. 8 (2018): 745-746. |
| Harvard | Balighi K et al. (2018) 'Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?', Journal of Dermatological Treatment, 29(8), pp. 745-746. |
| Vancouver | Balighi K, Ansari MS, Mirzaiepour M, Daneshpazhooh M, Mahmoudi H. Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?. Journal of Dermatological Treatment. 2018;29(8):745-746. |
| BibTex | @article{ author = {Balighi K and Ansari MS and Mirzaiepour M and Daneshpazhooh M and Mahmoudi H}, title = {Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option?}, journal = {Journal of Dermatological Treatment}, volume = {29}, number = {8}, pages = {745-746}, year = {2018} } |
| RIS | TY - JOUR AU - Balighi K AU - Ansari MS AU - Mirzaiepour M AU - Daneshpazhooh M AU - Mahmoudi H TI - Treatment of Basal Cell Carcinoma: Is Intralesional Methotrexate an Option? JO - Journal of Dermatological Treatment VL - 29 IS - 8 SP - 745 EP - 746 PY - 2018 ER - |